Ibandronsäure Bendalis (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronic acid binds to bone mineral surfaces and is taken up by osteoclasts during bone remodeling. Inside the cells it blocks the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway. This prevents essential protein prenylation, leading to osteoclast apoptosis and a reduction in bone breakdown.

The dose of Ibandronsäure Bendalis is determined by the prescribing clinician based on the patient’s specific indication, renal function, and overall health status. Only a qualified healthcare professional should set the dosing regimen, and it should be administered according to their instructions.

The safety of ibandronic acid in pregnancy and lactation has not been established. Because potential risks to the fetus or infant cannot be excluded, the product is generally avoided in pregnant or nursing women unless the potential benefit justifies the possible risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Ibandronsäure Bendalis delivers ibandronic acid, which has a high affinity for bone and a long skeletal retention time. Compared with older bisphosphonates such as alendronate, ibandronate may be administered less frequently (e.g., every three months intravenously) while offering similar efficacy in reducing vertebral fractures.

The product should be stored at ambient temperature, below 25 °C, in its original packaging. It must be protected from moisture and direct light. Before use, the vial should be inspected for particulate matter and only prepared by qualified personnel using aseptic technique.

Ibandronsäure Bendalis is given as an intravenous infusion. The healthcare professional prepares the solution according to the manufacturer’s instructions and administers it over the recommended infusion time, typically under medical supervision to monitor for acute reactions.

Serious adverse events include acute renal impairment, severe hypocalcemia, osteonecrosis of the jaw, and atypical femur fractures. Patients should be monitored for signs of kidney dysfunction, calcium disturbances, and any oral or skeletal pain that could indicate these rare but important complications.

Ibandronsäure Bendalis is contraindicated in patients with known hypersensitivity to ibandronic acid or any component of the formulation, in those with severe renal impairment (creatinine clearance < 30 mL/min), and in pregnant or nursing women due to unknown safety. Caution is also advised for individuals with low calcium levels.